Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks

Phase II Trial In Multiple Sclerosis Ongoing

 
• By Mandy Jackson
Question mark made by white pills spilling out of brown glass bottle on pink background
It remains to be seen if RIPK1 inhibition will succeed in the clinic • Source: Shutterstock

More from Clinical Trials

More from R&D